雷珠单抗玻璃体腔注射辅助显微手术治疗对新生血管性青光眼患者血管内皮生长因子和血小.

《雷珠单抗玻璃体腔注射辅助显微手术治疗对新生血管性青光眼患者血管内皮生长因子和血小.》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、治生影术皮的手内量微管含显t乎助者因辅患长艮产-I注光生腔青衍体性板璃管小玻血血抗生和单新子珠对因雷疗长响醒鈕獲歷罗峥岩川省江油市九O三医院眼科摘要：目的研究雷珠单抗玻璃体腔注射辅助显微手术治疗对新生血管性青光眼（NVG）患者血管内皮生长因子（VEGF）和血小板衍生生长因子（PDGF）含量的影响。方法对我院32例（32眼）NVG患荠资料进行回顾和分析，所有患考接受玻璃体腔注射雷珠单抗、小梁切除术和全视网膜光凝治疗。比较患者治疗前后眼压、视力、VEGF和PDGF，记录术后并发症和治疗成功率。结果32例患者随访（8.57±1.69）个月，

2、小梁切除术后1周、1个月、3个月、6个月眼压显著低于注药前，差异具有统计学意义（P〈0.05）:术后末次随访视力较注药前显著提高（P〈0.05）,视力提高率90.63%;患荞注药后5d和小梁切除术后1周、1个月、3个月、6个月房水、玻璃体液的VEGF和PDGE水平较注药前显著降低，差异具有统计学意义（P<0.05）:小梁切除术后前房出血率6.25%,包裹性滤过泡率6.25%,脉络膜脱落率3.13%;术后6个月手术成功率93.75%。结论雷珠单抗玻璃体腔注射辅助用于小梁切除术和全视网膜光凝治疗，可显著降低NVG患者VEGF和PDGF水平

3、，降低眼压、提高视力，安全有效。关键词：新生血管性青光眼;雷珠单抗;血管内皮生长因了;血小板衍生生长因收稿日期：2017-03-20EffectofIntravitrealInjectionofRanibizumabAssistedMicrosurgeryontheContentsofVascularEndothelialGrowthFactorsandPlatelet-derivedGrowthFactorsinPatientswithNeovascularGlaucomaHONGYongYUANLingLUONaGUDanLUOZ

4、hen-gyanDepartmentofOphtalmology，903HospitalofJiangyouCitySichuanProvince;Abstract：ObjectiveTostudytheeffectofintravitrealinjectionofranibizumabassistedmicrosurgeryonthecontentsofvascularendothelialgrowthfactors(VEGF)andplatelet-derivedgrowthfactors(PDGF)inpatientswithn

5、eovascularglaucoma(NVG).MethodsThedataof32patients(32eyes)withNVGinourhospitalwereanalyzedretrospectively.Allthepatientsweretreatedwithintravitrealinjectionofranibizumab,trabeculectomyandpanrentinalphotocoagulation.Theintraocularpressure(TOP),visualacuity，VEGFandPDGFwer

6、ecomparedbeforeandaftertreatment.Thepostoperativecomplicationsandsuccessrateoftreatmentwererecorded.ResultsAll32patientswerefollowedupfor(8.57土1.69)months.1week,1month,3monthsand6monthsaftertrabeculectomy,IOPwassignificantlylowerthanthatbeforetheinjection(P<0.05).Atthee

7、ndoffollow-up,thevisualacuitywassignificantlybetterthanthatbeforeinjection(P<0.05)，andimprovementrateofvisualacuitywas90.63%.5dafterinjection,1week,1month,3monthsand6monthsaftertrabeculectomy,thelevelsofVEGEandPDGFinaqueoushumorandvitreoushumorweresignificantlylowerthan

8、thosebeforeinjection(P<0.05).Therateofanteriorchamberhemorrhageaftertrabeculectomywas6.25%，therateofencapsulat